Minerva Neurosciences | NERV - Market Capitalization


Minerva Neurosciences reported $39.9M in Market Capitalization this April of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 4.52B 919M Dec/2025
Adma Biologics USD 4.34B 845M Dec/2025
ALKERMES USD 4.62B 333M Dec/2025
Alterity Therapeutics Limited AUD 30M 26M Apr/2026
AstraZeneca USD 288.15B 55.08B Dec/2025
BioCryst Pharmaceuticals USD 1.66B 64M Dec/2025
Bristol-Myers Squibb USD 109.81B 18.01B Dec/2025
Cipla INR 1.22T 6.47B Dec/2025
Clal Biotechnology ILS 43.45M 8.92M Mar/2026
Compugen USD 144.67M 7.17M Dec/2025
CSL USD 55.89B 20.42B Dec/2025
Eli Lilly USD 1.02T 293.84B Dec/2025
Esperion Therapeutics USD 885M 351M Dec/2025
GlaxoSmithKline GBP 74.36B 10.31B Dec/2025
Halozyme Therapeutics USD 7.91B 664M Dec/2025
Ionis Pharmaceuticals USD 12.81B 2.39B Dec/2025
J&J USD 578.59B 562M Apr/2026
Merck USD 261.26B 51.62B Dec/2025
Neurocrine Biosciences USD 14.14B 218M Dec/2025
Novartis USD 292.21B 26.55B Dec/2025
Novavax USD 1.09B 316M Dec/2025
Pfizer USD 141.57B 6.48B Dec/2025
Roche Holding CHF 266.34B 55.46B Dec/2025
Sanofi EUR 100.88B 4.46B Dec/2025
Takeda JPY 7.64T 774.9B Dec/2025
Vanda Pharmaceuticals USD 279M 6M Dec/2024